These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 34070899)
1. New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD). Patel P; Sheth V J Clin Med; 2021 May; 10(11):. PubMed ID: 34070899 [TBL] [Abstract][Full Text] [Related]
2. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Samanta A; Aziz AA; Jhingan M; Singh SR; Khanani AM; Chhablani J Asia Pac J Ophthalmol (Phila); 2020; 9(3):250-259. PubMed ID: 32511123 [TBL] [Abstract][Full Text] [Related]
3. Bruch's Membrane and the Choroid in Age-Related Macular Degeneration. Edwards M; Lutty GA Adv Exp Med Biol; 2021; 1256():89-119. PubMed ID: 33847999 [TBL] [Abstract][Full Text] [Related]
4. Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options. Tan CS; Ngo WK; Chay IW; Ting DS; Sadda SR Clin Ophthalmol; 2022; 16():917-933. PubMed ID: 35368240 [TBL] [Abstract][Full Text] [Related]
5. New Therapies of Neovascular AMD-Beyond Anti-VEGFs. Yerramothu P Vision (Basel); 2018 Jul; 2(3):. PubMed ID: 31735894 [TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic biomolecules in neovascular age-related macular degeneration; therapeutics and drug delivery systems. Kazemi MS; Shoari A; Salehibakhsh N; Aliabadi HAM; Abolhosseini M; Arab SS; Ahmadieh H; Kanavi MR; Behdani M Int J Pharm; 2024 Jun; 659():124258. PubMed ID: 38782152 [TBL] [Abstract][Full Text] [Related]
7. Beyond AREDS Formulations, What Is Next for Intermediate Age-Related Macular Degeneration (iAMD) Treatment? Potential Benefits of Antioxidant and Anti-inflammatory Apocarotenoids as Neuroprotectors. Camelo S; Latil M; Veillet S; Dilda PJ; Lafont R Oxid Med Cell Longev; 2020; 2020():4984927. PubMed ID: 33520083 [TBL] [Abstract][Full Text] [Related]
8. Anti-Vascular Endothelial Growth Factor Use and Atrophy in Neovascular Age-Related Macular Degeneration: Systematic Literature Review and Expert Opinion. Sadda SR; Guymer R; Monés JM; Tufail A; Jaffe GJ Ophthalmology; 2020 May; 127(5):648-659. PubMed ID: 32081493 [TBL] [Abstract][Full Text] [Related]
9. Factors Involved in Anti-VEGF Treatment Decisions for Neovascular Age-Related Macular Degeneration: Insights from Real-World Clinical Practice. Yiu G; Gulati S; Higgins V; Coak E; Mascia D; Kim E; Spicer G; Tabano D Clin Ophthalmol; 2024; 18():1679-1690. PubMed ID: 38860119 [TBL] [Abstract][Full Text] [Related]
10. Effect of Adjuvant Topical Dorzolamide-Timolol vs Placebo in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. Hsu J; Patel SN; Wolfe JD; Shah CP; Chen E; Jenkins TL; Wibbelsman TD; Obeid A; Mikhail M; Garg SJ; Ho AC; Chiang A; Spirn MJ; Vander JF JAMA Ophthalmol; 2020 May; 138(5):560-567. PubMed ID: 32239190 [TBL] [Abstract][Full Text] [Related]
11. Evolution of oxidative stress, inflammation and neovascularization in the choroid and retina in a subretinal lipid induced age-related macular degeneration model. Kim SY; Kambhampati SP; Bhutto IA; McLeod DS; Lutty GA; Kannan RM Exp Eye Res; 2021 Feb; 203():108391. PubMed ID: 33307075 [TBL] [Abstract][Full Text] [Related]
19. Summary of the Therapeutic Options for Patients with Dry and Neovascular AMD. Śpiewak D; Drzyzga Ł; Dorecka M; Wyględowska-Promieńska D J Clin Med; 2024 Jul; 13(14):. PubMed ID: 39064267 [TBL] [Abstract][Full Text] [Related]
20. New Treatment Modalities for Neovascular Age-Related Macular Degeneration. Schlottmann PG; Alezzandrini AA; Zas M; Rodriguez FJ; Luna JD; Wu L Asia Pac J Ophthalmol (Phila); 2017; 6(6):514-519. PubMed ID: 28933517 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]